A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01313143
Recruitment Status : Completed
First Posted : March 11, 2011
Last Update Posted : July 19, 2012
Information provided by (Responsible Party):
AOP Orphan Pharmaceuticals AG

March 10, 2011
March 11, 2011
July 19, 2012
March 2011
May 2011   (Final data collection date for primary outcome measure)
Pharmacokinetics/dynamics [ Time Frame: 9 hours ]
Same as current
Complete list of historical versions of study NCT01313143 on Archive Site
Local tolerability [ Time Frame: 9 hours ]
Same as current
Not Provided
Not Provided
A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol
A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects.
Pharmacokinetics, pharmacodynamics and tolerability of AOP200704 infusion is compared to that of Esmolol by measurement of plasma concentrations of AOP200704, esmolol and their metabolites, by assessing the effect of both drugs on dobutamine-induced tachycardia, and by monitoring vital signs, ECG and adverse events.
16 healthy volunteers of both sexes, age 18 to 45 years, will be enrolled. The mean dose necessary to suppress the Dobutamine induced heart rate increase of at least 30 bpm above baseline rate (maximum heart rate app. 110 bpm) by at least 20 bpm will be calculated for AOP200704 and Esmolol and the dose/efficacy relation of both agents to each other will be calculated for the steady state condition. For both drugs the time to reach a decrease of 10 bpm, 20 bpm and the maximum effect will be calculated. In addition the mean time to increase in 10 and 20 bpm and the time to reach maximum heart rate (increase of 30 bpm above baseline or more) after termination of infusion will also be assessed for both drugs. Blood pressure values will be compared for all above mentioned time points where heart rate is assessed for pharmacodynamics.The study will consist of a screening, cross-over 1, cross-over 2 and end-of-study visit.
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Healthy Volunteers
  • Pharmacokinetics/Dynamics Study
  • Drug: AOP200704
    Comparison of AOP200704 with Esmolol
  • Drug: Esmolol hydrochloride, infusion
    Comparison of AOP200704 with Esmolol
  • Experimental: AOP200704, infusion
    Intervention: Drug: AOP200704
  • Active Comparator: Esmolol, infusion
    Intervention: Drug: Esmolol hydrochloride, infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
January 2012
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female human subjects, age 18-45 years
  • Body weight of at least 50 kg, maximum of 90 kg. Body-mass index 18.5 to 30.0 kg/m2
  • Caucasians
  • Subjects without clinically relevant abnormalities
  • Subjects agreeing to not using any prescription and over the counter medications including vitamins and minerals for 7 days prior to study and during the course of the study
  • No drug or alcohol abuse
  • Non-smokers, ex smokers and mild smokers

Exclusion Criteria:

  • Subjects with history or presence of clinically relevant cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological, psychiatric or skin diseases.
  • Subjects with bradycardia (heart rate below 50 bpm), tachycardia (heart rate above 100 bpm), hypotension (systolic blood pressure below 100 mmHg, and/or diastolic blood pressure below 70 mm Hg) at screening, clinically relevant or history of clinically relevant arrhythmias
  • Subjects with clinically relevant cardiac supraventricular or ventricular arrhythmias.
  • Subjects with atrioventricular block of grade II and III, sick sinus syndrome, sinoatrial block or congestive heart failure
  • Participation in a clinical drug study or bioequivalence study 60 days prior to present study.
  • History of malignancy or other serious diseases.
  • Any contraindication to blood sampling.
  • History of i.v. drug abuse.
  • Subjects with positive HIV tests, HBsAg or Hepatitis C tests or other acute, subacute or chronic infectious disease.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Czech Republic
Not Provided
Not Provided
AOP Orphan Pharmaceuticals AG
AOP Orphan Pharmaceuticals AG
Not Provided
Principal Investigator: AOP Study Principal Investigator AOP Contract Clinical Research Facility
AOP Orphan Pharmaceuticals AG
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP